6Trost S,Pratley R,Sobel B.Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.Curr Diab Rep,2006,6(1):47-54.
7Qi Q,Wang J,Li H,et al.Associations of resistin with inflammatory and fibrinolytic markers,insulin resistance,and metabolic syndrome in middle-aged and older Chinese.Eur JEndocrinol,2008,159 (5):585-593.
8Heldgaard PE,Sidelmann JJ,Hindsberger C,et al.Relationship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance.Diabet Med,2006,23(8):887-893.
9Serrano R,Barrenetxe J,Orbe J,et al.Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats.Am J Physiol Regul Integr Comp Physiol,2009,297 (5):R1563-1569.
10Sobel BE,Tilton L,Neimane D,et al.Increased tissue-type plasminogen activator:a facade in the fibrinolytic system in type 2 diabetes.Coron Artery Dis,2005,16(1):31-35.
5Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int, 1999,56(5):1627 - 1637.
6Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2000,414 (6865) : 813 - 820.
7Ichimura T,Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule- 1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest, 2008,118 (5) : 1657 - 1668.
8Lee HB, Ha H. Piasminogen activator inhibitor - 1 and diabetic nephropathy. Nephrology, 2005,10 (Suppl) : S11 - S13.
9Eddy AA, Fogo AB. Plasminogen activator inhibitor - 1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol,2006,17(11) :2999 - 3012.
10Rerolle JP, Hertig A, Ngugen G, et al. Plasminongen activatior inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int,2000,58(5) : 1841 - 1850.
